(RTTNews) - Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of ...
Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII ...
Snubbed by Tesla, Mexico's new president pledged Friday to create a Mexican-made small, affordable electric car to compete ...
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...
Recent health developments include HIV infections from organ transplants in Brazil, Sanofi's potential sale of a stake in its ...
The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...
Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...
The FDA has approved Pfizer’s marstacimab under the brand name Hympavzi for adults and children with hemophilia A or B, ...
The Food and Drug Administration approved Pfizer's Hympavzi to prevent or reduce bleeding episodes in patients with certain kinds of hemophilia A and B. "Pfizer's Hympavzi Approved for Treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback